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Genotype scores predict drug efficacy in 
subtypes of female sexual interest/arousal 
disorder: A double-blind, randomized, 
placebo-controlled cross-over trial
Adriaan Tuiten1, Frits Michiels2, Koen BE Böcker3,  
Daniël Höhle3, Jack van Honk4,5,6, Robert PJ de Lange3,  
Kim van Rooij1,7, Rob Kessels1, Jos Bloemers1,7,  
Jeroen Gerritsen1,7, Paddy Janssen8,9, Leo de Leede10,  
John-Jules Meyer3,11, Walter Everaerd12, Henderik W Frijlink13, 
Hans PF Koppeschaar1, Berend Olivier7,14,15 and James G Pfaus16
Abstract
Attempts to develop a drug treatment for female sexual interest/arousal disorder have so far been guided by the 
principle of ‘one size fits all’, and have failed to acknowledge the complexity of female sexuality. Guided by personalized 
medicine, we designed two on-demand drugs targeting two distinct hypothesized causal mechanisms for this sexual 
disorder. The objective of this study was to design and test a novel procedure, based on genotyping, that predicts 
which of the two on-demand drugs will yield a positive treatment response. In a double-blind, randomized, placebo-
controlled cross-over experiment, 139 women with female sexual interest/arousal disorder received three different on-
demand drug-combination treatments during three 2-week periods: testosterone 0.5 mg + sildenafil 50 mg, testosterone 
0.5 mg + buspirone 10 mg, and matching placebo. The primary endpoint was change in satisfactory sexual events. 
Subjects’ genetic profile was assessed using a microarray chip that measures 300,000 single-nucleotide polymorphisms. A 
preselection of single-nucleotide polymorphisms associated with genes that are shown to be involved in sexual behaviour 
were combined into a Phenotype Prediction Score. The Phenotype Prediction Score demarcation formula was developed 
and subsequently validated on separate data sets. Prediction of drug-responders with the Phenotype Prediction Score 
demarcation formula gave large effect sizes (d = 0.66 through 1.06) in the true drug-responders, and medium effect sizes 
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(d = 0.51 and d = 0.47) in all patients (including identified double, and non-responders). Accuracy, sensitivity, specificity, 
positive predictive value, and negative predictive value of the Phenotype Prediction Score demarcation formula were 
all between 0.78 and 0.79, and thus sufficient. The resulting Phenotype Prediction Score was validated and shown to 
effectively and reliably predict which women would benefit from which on-demand drug, and could therefore also be 
useful in clinical practice, as a companion diagnostic establishing the way to a true personalized medicine approach.
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phenotype prediction score, satisfactory sexual events, single-nucleotide polymorphisms, testosterone
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Low sexual desire and/or arousal are the most common 
sex-related complaints reported by women.1,2 They often 
result in sexual dissatisfaction, which in turn impacts psy-
chological well-being and can result in severe personal 
distress.3 These complaints are classified in the Diagnostic 
and Statistical Manual for Mental Disorders, edition 5 
(DSM-5)4 as female sexual interest/arousal disorder 
(FSIAD). The disorder is likely caused by a complex 
interaction of psychological and neurobiological fac-
tors5–7 and is prevalent among women of all ages8 and eth-
nicities.9 While effective pharmacological treatments for 
erectile dysfunction (ED) have been available for two 
decades now,10 the development of effective and safe drug 
treatments for sexual dysfunction in women has met with 
only limited success. Flibanserin recently became availa-
ble for treatment of premenopausal women with FSIAD11 
in the United States, and later in Canada, but it shows poor 
efficacy and produces a range of adverse effects. This 
drug requires the use of an extensive risk evaluation and 
mitigation strategy to prevent untoward adverse effects. 
Moreover, no drug treatment is yet available outside 
North America.
In seeking effective treatment for FSIAD, we have 
adopted a hypothesis-driven, personalized sexual medicine 
approach,12–15 based on established neurobiological mecha-
nisms known to either promote or inhibit sexual desire.5 We 
have identified a subgroup of women with FSIAD in which 
the brain systems for sexual excitation are relatively insensi-
tive, resulting in low sexual desire/arousal. In addition, we 
have identified another substantial subgroup of women in 
which exposure to sexual stimulation dysfunctionally 
increases the activity of inhibitory sexual mechanisms. This, 
too, results in low sexual desire/arousal. The neurobiologi-
cal mechanism involved in this inhibitory effect likely 
involves a phasic increase in serotonergic activity in the left 
dorsolateral prefrontal cortex (DLPFC),5,12 which is elicited 
by sexual stimulation. This subgroup division is based on 
the dual-control model of sexual response16 and is substa-
ntiated by cognitive,15,17 psychophysiological,13–15,17,18 sub-
jective,13–15,19 neuroanatomical,12,20 and pharmacological 
evidence.13–15,17,19 Unfortunately, it is not readily apparent to 
which category a patient belongs because the symptoms, 
low desire and/or low arousal, manifest in the same manner 
in both these subgroups. To summarize, it is believed that 
while low sensitivity to sexual cues is associated with low 
sexual desire and arousal, high sensitivity to sexual cues can 
also result in low desire/arousal if sexual stimulation elicits 
a dysfunctionally high sexual inhibition response.5,12
Accordingly, we have developed two different drug 
treatments targeted at these two distinct neurobiological 
mechanisms. The administration of a single dose of 0.5 mg 
sublingual testosterone (T) produces a peak in plasma 
level of T within 15 minutes, with a return to baseline 
within 2 hours. However, in a period ranging from 3 to 
6 hours after peak plasma levels, sublingual T produces an 
increase in vaginal arousal and in subjective sexual 
responses in sexually functional women.21,22 The devel-
oped treatments consist of novel (dual-route/dual-release, 
fixed-dose) combination tablets consisting of a T coating 
for sublingual administration, and an inner-core compo-
nent containing the phosphodiesterase type 5 (PDE-5) 
inhibitor sildenafil (S) or the 5HT1A receptor agonist bus-
pirone (B). The inner-core component is coated with a 
delayed-release matrix to ensure that the peak plasma con-
centration of S or B, respectively, coincides with the win-
dow of increased sexual motivation induced by the 
sublingual T. T + S has been developed for women with 
FSIAD and a relative insensitivity to sexual cues, and 
T + B for women with FSIAD and a dysfunctional activa-
tion of sexual inhibitory mechanisms. Earlier proof of con-
cept experiments showed that both combinations (T + S 
and T + B) are promising potential on-demand treatments 
for two subtypes of women with FSIAD.13,14 A description 
and explanation of the working mechanisms of the two 
drugs can be found in the Supplementary information.
To predict which of the two drug treatments will be 
effective for a woman diagnosed with FSIAD, we have 
searched for (combinations of) biological and psychological 
markers related to either one or both of the two distinct neu-
robiological mechanisms underlying FSIAD. An emotional 
Stroop task13,15,17 and a combination of questionnaires and 
biological markers19 were to a sufficient extent effective 
in separating T + S and T + B responders; however, this 
solution was deemed impractical for the clinical setting. 
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Therefore, we searched for combinations of genetic markers 
that reflect the aetiology of the phenotype and thus predict 
the responses to these drugs. We selected genetic markers 
from candidate genes associated with neurobiological 
mechanisms involved in the regulation of sexual behav-
iour. We combined the contribution of the selected genetic 
markers into a single score that predicts the phenotypes: 
the Phenotype Prediction Score (PPS).
There were four reasons for not applying an approach 
in which single-nucleotide polymorphisms (SNPs) for the 
PPS are selected based on a hypothesis-free genome wide 
association study (GWAS)23–25 First, it would discard the 
current neurobiological knowledge of female sexual 
behaviour from our hypothesis-driven approach. Second, 
it would require thousands of women diagnosed with 
FSIAD, treated with both drugs, to obtain sufficient statis-
tical power. Third, in recent (GWAS) studies of low sexual 
desire/arousal in women, only a few weak associations 
(oestrogen 2 receptor SNP rs4986938 was nominally sig-
nificantly associated with both desire and lubrication 
before but not after correction for multiple testing)26 or no 
significant associations27 were found. Fourth, the present 
research is focussed on only one symptom, low sexual 
desire/arousal, for which we assume that different causal 
neurobiological mechanisms are responsible. From a logi-
cal point of view, it would be impossible to find a risk SNP 
for one symptom with different (opposing) causal mecha-
nisms among individuals.
The low penetrance of individual genetic loci often 
means that no single genotype could determine or predict 
a phenotype.28,29 Accordingly, we adopted an alternative 
approach that was more suited to FSIAD’s complex nature 
and its phenotypes. Fisher30–32 noted that traits influenced 
by multiple genes will have normal distributions, as quan-
titative traits. Thus, complex disorders affected by multi-
ple genes, such as FSIAD, can be studied as quantitative 
traits.33 Some individuals carry few genetic risk factors 
while others have many. The majority of the population 
will be clustered around the mean.
Our novel approach of the genetic subtyping of FSIAD 
patients, resulting in a PPS, was based on: (1) a selection 
of genes that affect neurochemical systems known to be 
involved in the regulation of female sexual behaviour5,26 
(see Supplementary information); (2) selection of SNPs 
associated with these genes (see for comparable hypothe-
sis and genetic-driven selections of SNPs34–36); and (3) cal-
culation of cumulative effect of multiple selected SNPs 
that emerged, resulting in the final PPS.
Method
To develop an SNP-based subtyping system, we carried 
out a double-blind, randomized, placebo-controlled, cross-
over experiment in 139 women with FSIAD. After a 
2-week baseline measurement, in which they received 
placebo (single-blind placebo run-in period or PRI), the 
women were randomly assigned to different 2-week, dou-
ble-blind, on-demand drug treatment periods. The primary 
endpoint in this experiment was an increase in the number 
of satisfactory sexual events (SSEs) between PRI and the 
active treatments (T + S; T + B). The experimental design 
included a within-comparison; therefore, the results for 
each participant consisted of two drug effects, one for 
T + S and one for T + B. For the purpose of our novel PPS 
procedure, we calculated a single-outcome measure, which 
incorporated both drug effects.
In developing the SNP-based subtyping system, we 
started by selecting a relatively small number of SNPs, 
based on a hypothesis-driven selection of genes involved 
in regulating sexual behaviour (see Supplementary infor-
mation). The SNPs considered were those located inside 
these candidate genes or their promotor regions, or those 
located between a candidate gene and a neighbouring 
gene. From this selection, the SNPs with potential predic-
tive value in terms of the response to each of both FSIAD 
treatments were distilled. These SNPs were combined 
into the PPS, creating a classification system that differ-
entiates T + S and T + B responders based on a women’s 
genetic profile. The PPS demarcation formula was devel-
oped in a derivation sample and then validated using an 
independent sample.
Study aim
To develop and validate an SNP-based demarcation for-
mula intended to predict the efficacy of two different drugs 
in two distinct subgroups of women with FSIAD. For this 
purpose, we used a clinical experiment to investigate the 
difference in efficacy of T + S (0.5 mg sublingual testos-
terone combined with 50 mg sildenafil) and T + B (0.5 mg 
sublingual testosterone combined with 10 mg buspirone) 
compared to placebo, in women with FSIAD.
Study participants
Women between the ages of 18 and 70 were recruited via 
advertisements and from a database of volunteers (main-
tained by Emotional Brain BV, Almere, The Netherlands). 
Determination of the required sample size was done by a 
receiver operating characteristic (ROC) curve power anal-
ysis. Assuming a balanced design of 75 cases in each pre-
dicted group, 90% statistical power was required to detect 
a minimum area under the curve (AUC) of 0.65. After 
providing written informed consent, 218 women were 
screened for eligibility. Diagnoses of FSIAD were based 
on a semi-structured interview (see Supplementary infor-
mation) that was conducted by two trained psychologists 
and were based on the DSM-5.4 Individuals exhibiting 
comorbidity with female orgasmic disorder (as a second-
ary diagnosis) were not excluded. The subjects’ medical 
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history was recorded, after which they were given a physi-
cal examination, including a 12-lead electrocardiogram 
and a urine pregnancy test. The standard biochemical, 
serological, and haematological laboratory parameters 
were assessed. Baseline levels of total testosterone (to 
rule out hyperandrogenism), sex hormone-binding globu-
lin, albumin, thyroid stimulating hormone, follicle-stimu-
lating hormone, luteinizing hormone, prolactin, and 
oestrogen, were also assessed at screening. The partici-
pants included in the final analyses were involved in a 
stable, communicative, monogamous relationship and had 
a sexually functional partner, had a normal medical his-
tory, and were otherwise healthy as determined by the 
physical examination, laboratory values, and vital signs 
(see CONSORT diagram, Figure 1). Demographics of all 
randomized participants (N = 163) are presented in Table 1.
Study performance and approval
Between 7 February 2014 (first screening visit) and 12 
August 2014 (last follow-up visit, as per protocol), the 
study was conducted by trained research staff at two clini-
cal research units of Emotional Brain BV (Almere and 
Utrecht) and monitored by PSR Group (Hoofddorp, The 
Netherlands). It was performed in compliance with the 
Declaration of Helsinki (October 2008) and with the 
International Conference on Harmonization – Good 
Clinical Practice guidelines for clinical research. The study 
Figure 1. Consort diagram.
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was approved by a Medical Ethics Committee ‘Stichting 
BEBO’ (Assen, The Netherlands) and by the Dutch 
Competent Authority (Centrale Commissie Mensgebonden 
Onderzoek), under authorization number NL44803.056.13. 
It was registered in the European Clinical Trials Database, 
as EudraCT number 2011-000457-23. The trial was regis-
tered under Primary Registry trial number NTR4426 
(Netherlands Trial Register).
Study design
The study was a randomized, double-blind, placebo- 
controlled, cross-over study. It included a 2-week single-
blind placebo run-in period (PRI),resembling baseline 
measurements during the phase 2 and planned phase 3 
experiments, and three 2-week double-blind treatment 
periods (placebo, T + S, and T + B), with a 1-week follow-
up period. Each regimen was separated by at least one 
2-day wash-out period. (note that both drugs are intended 
for on-demand use and that systemic clearance takes 
approximately 24 hours.) Each participant completed the 
three 2-week treatment periods in a randomized order, in 
accordance with a 6-sequence Williams design (see Figure 2). 
Treatment sequences were listed in a randomization list gen-
erated by independent statisticians at the Pharma Consulting 
Group (Uppsala, Sweden). Those who were eligible to par-
ticipate in the study were randomized and allocated a treat-
ment sequence by the principle investigator, using an 
interactive web-response system that was an integral part of 
the electronic case report form (Viedoc™, version 3.22; 
Pharma Consulting Group, Uppsala, Sweden). The unique 
3-digit code allocated to each participant coincided with a 
unique 3-digit treatment code on each medication container. 
Prior to database lock, none of the study participants, none 
of the research staff involved, nor anyone employed by the 
sponsor had access to the randomization list.
Each of the participants visited the study site on a total 
of seven occasions. These consisted of one screening visit, 
one start-up visit, four study regimen follow-up visits, and 
one final follow-up visit. During the start-up visit and study 
regimen follow-up visits, an evaluation was made of each 
individual’s sexual functioning, their health was monitored, 
and study medication was dispensed. At the start-up visit, 
blood was drawn for the assessment of the SNPs.
The primary endpoint was the change in the total num-
ber of SSEs after medication intake between the single-
blind placebo run-in period (PRI) and the double-blind 
active treatment period (ATP), as measured by the sexual 
event diary (SED). This is a more adequate endpoint for 
testing the efficacy of on-demand drugs than question-
naires assessing sexual functioning over longer periods of 
time (e.g. the preceding 4 weeks) as the observation is 
more proximate to an on-demand drug’s efficacy.
SED
The SED is an 11-item, standardized quantitative scale, for 
which validated US-English37 and Dutch38 versions are 
available. Eight of these items (sexual satisfaction, sexual 
desire, physical arousal, mental arousal, sexual pleasure, 
orgasm, distraction, and inhibition) assess the individual’s 
sexual functioning during a single sexual event. The 
remaining three items assess the type and time of the sex-
ual event, and whether the on-demand medication was 
used (as instructed). This questionnaire is filled out within 
24 hours of the event. Only those events during which 
medication was used were analysed.
Medication, dosing, and instructions
Sublingual T + S. It is a dual-route/dual-release fixed-dose 
combination of T and S citrate.39 The drug product is a 
9-mm, round, biconvex, white, menthol-flavoured tablet 
for sublingual administration. The outer coating (a poly-
meric film) contains testosterone (0.5 mg) that is released 
Table 1. Demographics all randomized participants.
Parameter Number of participants (%)
Total (N = 163)
Age (category)  
 <40 105 (64.4)
 40–60 50 (30.7)
 ⩾60 8 (4.9)




Body mass index  
 <35 160 (98.2)
 ⩾35 3 (1.8)
Menopausal status  
 Post-menopausal 28 (17.2)
 Pre-menopausal 135 (82.8)
Denominator for the calculation of percentages: total number of 
participants randomized.
Figure 2. Study and randomization design.
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immediately on sublingual administration. The inner core 
of the tablet, which contains sildenafil (50 mg), has a poly-
meric coating designed to delay the release of that drug for 
approximately 2.5 hours. When that period elapses, the 
sildenafil is released immediately (i.e. there is no sustained 
release).
Sublingual T + B. It is a dual-route/dual-release fixed-dose 
combination of T and B hydrochloride.40 The drug product 
is a 9-mm, round, biconvex, white, menthol-flavoured tab-
let for sublingual and oral administration. The appearance, 
method of administration and flavour of T + B is identical 
to T + S. The outer, polymeric-film coating contains tes-
tosterone (0.5 mg) that is released immediately on sublin-
gual administration. The inner core of the tablet contains 
buspirone hydrochloride (10 mg). This inner core has a 
polymeric coating designed to delay the release of bus-
pirone for approximately 2.5 hours. When that period 
elapses, the buspirone is released immediately (i.e. there is 
no sustained release).
Placebo. The placebo tablets were identical, in terms of 
appearance and flavour, to the fixed-dose combination T + S 
and T + B tablets containing the active pharmaceutical 
ingredients. All of the medication used was manufactured 
and packaged at Piramal Healthcare UK (Morpeth, UK).
Dosing instructions. The participants were instructed to 
keep the tablet under their tongue for 90 seconds and then 
to swallow it whole, without chewing it or otherwise dis-
rupting the dosage form. They were permitted to take the 
tablet with a little water. The subjects were instructed to 
engage in sexual activity between 3 and 6 hours after 
ingestion. The dosing instructions were the same for all 
medications.
Duration of treatment. A total of eight doses per regime 
were provided. The participants were asked to endeavour 
to take a minimum of four doses during the 2-week treat-
ment periods (two doses/week). They were informed that 
they could take the remaining four doses as required (i.e. 
‘on demand’) throughout the 2-week treatment period. The 
minimum period between individual doses was two days 
(i.e. on alternate days).
SNP analysis
DNA extraction was performed by Medigenomix 
(Ebersberg, Germany). SNP analysis was performed using 
a microarray chip (HumanCytoSNP-12 bead chip, Illumina, 
containing 297,622 SNPs). The hybridization and chip 
readout were performed by Eurofins (The Netherlands), 
AROS Applied Biotechnology (Aarhus, Denmark), and 
Medigenomix (Ebersberg), specialized laboratory service 
providers.
Statistical methods
Missing data and imputation. If participants failed to fill out 
an SED within a 2-week period, this resulted in missing data. 
This meant that either the participant did not experience a 
sexual event or that they did, but then forgot to report it. 
The percentage of missing SEDs during PRI was 2.9%, 
while during the placebo regime it was 6.5%. The corre-
sponding values for the T + S regime and the T + B regime 
were 5.0% and 3.6%, respectively. Those participants who 
only reported SED in a single regime, or who reported no 
SEDs at all, were eliminated from the analysis. Those who 
reported SEDs in at least two regimes were imputed. The 
missing SEDs were imputed by first imputing the number 
of events involved (by sampling participants with similar 
response patterns). Then, the corresponding Likert-type 
scale items were imputed by the mean, based on partici-
pants with the same number of events.
Statistical analyses. Group-level statistics and patient-level 
statistics were derived to assess the efficacy, usefulness, 
and validity of the formula. Group-level analyses were 
performed using paired sample t-tests to assess the change 
from PRI to T + S and to T + B. This was assessed for the 
derivation sample (N = 50), validation sample (N = 47), 
and total sample (N = 97) of observed responders. T + S 
response is defined as having more SSEs in the T + S than 
T + B condition. T + B response is defined as having more 
SSEs in the T + B than T + S condition. Furthermore, util-
ity was tested for all participants, including observed non-
responders (N = 139). A multiplicity correction was applied 
by controlling the false discovery rate (FDR), to control 
for inflated Type 1 error rates. In addition to p-values, 
effect sizes (Cohen’s d) were calculated using the formula 
for paired sample t-tests, as defined in Dunlop et al.41
Utility at patient-level was tested by deriving an ROC 
curve for the total sample (N = 97) of observed respond-
ers. The AUC of the ROC curve served as the test statistic 
for the relationship between demarcation formula out-
come and response status based on the outcome measure. 
The hypothesis tested was that, when used to classify 
women as either T + S or T + B responders, the formula 
would perform above chance level. The AUC can be inter-
preted as the probability that, for a given random pair 
(T + S responder plus a T + B responder), the formula 
would produce a larger outcome for the former than for 
the latter. ROCs with an AUC in excess of 0.714 indicated 
a large effect size (d’ > 0.8), while ROCs with an AUC in 
excess of 0.76 indicated an effect size of at least 1.42 
Finally, ROCs with an AUC in excess of 0.80 were gener-
ally considered to be ‘good’, and suitable for clinical use. 
Besides the ROC curve with corresponding AUC, classi-
fication performances were also calculated for the total 
sample of observed responders. These involved accuracy, 
sensitivity, specificity, positive predictive value (PPV), 
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Table 2. PPS SNP composition.
SNP identifier Gene Abbreviation Implicated in
rs963468 Dopamine D3 receptor DRD3 Wanting*
rs2770296 5-HT2a receptor HTR2A Novelty seeking
rs11168048 5-HT4 receptor HTR4 Mediator of the neurogenic and behavioural actions of 
antidepressants*
rs3740046 5-HT7 receptor HTR7  
rs140701 5-HT Transporter SLC6A4 Alcohol intake behaviour, schizophrenia, panic disorder
rs13278849 Adrenoreceptor alpha 1A ADRA1A Olfactory-driven behaviours*
rs1079078 Adrenoreceptor alpha 1A ADRA1A Olfactory-driven behaviours*
rs10515805 Adrenoreceptor alpha 1B ADRA1B Lordosis*
rs12653825 Adrenoreceptor alpha 1B ADRA1B Lordosis*
rs41154 NE transporter SLC6A2  
rs6259 SHGB  
rs7761133 Oestrogen 1 receptor ESR1  
rs1256114 Oestrogen 2 receptor ESR2  
rs7734558 Prolactin  
rs816353 Nitric oxide synthase NOS1 Vasodilation
rs48255 Nitric oxide synthase NOS1 Vasodilation
SNP: single-nucleotide polymorphism; SHGB: sex hormone–binding globulin; NE: norepinephrine.
See supplementary information for a full overview of these SNPs and their implicated function.
*Gene implicated, SNP not described in the literature.
and negative predictive value (NPV). These classification 
performance statistics are usually used to obtain informa-
tion about the ability of companion diagnostic tools to 
identify women with and without a given diagnosis. In 
this application, the tool was designed to classify women 
as either T + S or T + B responders, and these classifica-
tion performances were interpreted accordingly. In this 
context, accuracy was reflected by the proportion of 
women classified correctly, while sensitivity corre-
sponded to the formula’s ability to identify T + B respond-
ers. Specificity was defined as the ability to identify T + S 
responders, PPV as the proportion of correctly identified 
T + B responders, and NPV as the proportion of correctly 
identified T + S responders.
Results
The development of the PPS resulted in the combination of 
16 SNPs (see Table 2).
Figure 3 shows that the two FSIAD subtypes classified 
by the PPS demarcation formula (calculated as a dichot-
omy) exhibited clear improvements in symptoms in both 
the derivation and validation samples. This supports the 
validity of the PPS demarcation formula at the level of the 
responder group, which showed large effect sizes (d = 0.66–
1.06). Moreover, the effects in all patients (including iden-
tified double, and non-responders) also showed the 
expected drug responses, and medium effect sizes (d = 0.51 
and d = 0.47). Figure 3(g) shows the ROC curve of the 
PPS, which supports the utility of the PPS at the individual 
level as well.
T + S and T + B were well tolerated and no drug related 
serious adverse events were observed. None of the adverse 
events led to discontinuation of the study drug. Most 
adverse events were characterized as mild or moderate in 
severity and were consistent with the approved labelling 
for S, B and/or T. See Table 3 for the most common treat-
ment-emergent adverse events per drug condition.
Discussion
The idea behind the PPS method is that disorders like 
FSIAD result from an interplay between genetic back-
ground, past experiences, and present circumstances. Even 
though it is based solely of biological variables, it accounts 
for both biological and psychological mechanisms. For 
example, high sexual inhibition might result from the com-
bination of genetic factors that increase the brain’s sensi-
tivity to sexual cues and adverse sexual experiences. A 
highly sensitive system to sexual stimuli combined with 
positive sexual experiences may lead to a pleasant and 
enjoyable sexual life. However, adverse sexual experi-
ences may have a greater impact on those whose brains are 
more sensitive to sexual cues. This combination of a highly 
sensitive brain and adverse experiences may lead to a 
learned and autonomous sexual inhibitory response, in 
which sexual events and adverse associations are automat-
ically linked. The concept of a dichotomous measure, 
which closely reflects a contrast in content-meaning, ena-
bled us to identify risk genotypes that were linked to a 
series of SNPs and which may have opposing roles in 
terms of brain activity. This view reflects the possibility 
8 Women’s Health 
Figure 3. (a, b, c, and d) The mean drug responses for responders in the derivation sample (N = 50), validation sample (N = 47), 
and total sample (N = 97) are shown for the primary endpoint of predicted T + S responders (N = 24, 25, and 49 for the derivation, 
validation, and total samples of responders, respectively; Panels a and d) and of predicted T + B responders (N = 26, 22, and 48 for 
the derivation, validation, and total samples, respectively; Panels b and c). Panels A and B are the results for the T + S responses ((a) 
T + S response for the predicted T + S responders, and (b) T + S response for the predicted T + B responders), while panels c and 
d are the results for the T + B responses ((c) T + B response for the predicted T + B responders and (d) T + B response for the 
predicted T + S responders). (e and f) The mean drug responses on the primary endpoint are shown for all participants (N = 139, 
including identified double-, and non-responders) in Figure 3, panels e and f. Panel e shows the response on the primary endpoint 
of T + S treatment for the predicted T + S responders (N = 67) and for the predicted T + B subgroup (N = 72). Panel f reveals the 
effect of treatment with T + B on the primary endpoint in the predicted T + S responders and the predicted T + B responders.
(Continued)
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that opposing causal mechanisms could be responsible for 
low sexual desire/arousal.
This study has several limitations. The microarray chip 
used in the study contained 300,000 SNPs out of a possible 
10 million, approximately. It is very well possible that 
another combination of SNPs exists that yield a better pre-
diction. We have focussed on SNPs from a limited number 
of genes that have been associated with female sexual 
behaviour, in literature. It is, of course, conceivable that 
SNPs from other genes whose role in female sexual behav-
iour is still unclear, may improve the response prediction. 
Also, the study had a relatively low number of subjects. 
This increases the likelihood that the results are not fully 
generalizable to the full FSIAD population. The setup 
of the analyses however, using separate derivation and 
validation sets, and the medium to large effect sizes, do 
increase the likelihood of this generalizability. Future 
research will need to establish if other SNPs/genes are even 
better predictors and if the results are generalizable. 
Moreover, it would be interesting to see whether this condi-
tional genotyping method is also able to predict treatment 
outcome in other psychological/psychiatric disorders.
In conclusion, we have demonstrated that our condi-
tional method that can be used to describe traits (i.e. dif-
ferentiated treatment effects) partly in terms of unique sets 
of mutually exclusive risk genotypes. Moreover, combin-
ing the identified SNPs resulted in a PPS that could be 
used to predict correct drug responses in identified sub-
types where these drugs would be expected to have an 
effect. The classification results at the individual level 
Table 3. Incidence of most common treatment-emergent adverse events per drug condition.
SOC Term (MeDRA) Study drug
Placebo Lybrido Lybridos
Gastrointestinal disorders  
 Nausea 2 (1.2) 8 (4.9) 13 (8)
Nervous system disorders  
 Dizziness 3 (1.8) 7 (4.3) 38 (23.3)
 Headache 10 (6.1) 28 (17.2) 10 (6.1)
Respiratory, thoracic and mediastinal disorders  
 Nasal congestion 1 (0.6) 10 (6.1) 1 (0.6)
Vascular disorders  
 Flushing 1 (0.6) 11 (6.7) 4 (2.5)
 Total 17 64 66
MeDRA: Medical Dictionary of Regulatory Activities; SOC: system organ class.
Adverse events that were summarized were reported after Visit 2 and before Visit 5 (or last intake investigational study drug).
Subjects with one or more adverse events within a level of the MeDRA term were counted only once for that level, except when study drug dif-
fered for the same event.
Most common is defined as ⩾ 5% in any of the drug conditions.
Denominator for the calculation of percentages: total number of subjects randomized.
(a, b, c, d, e, and f) Each of the treatments was taken for 2 weeks, yet the data represent the mean number of SSEs over a 4-week period (to make 
it comparable with the results of similar experiments in this field). The reported p-values are two-sided. Error bars represent the standard error 
of the mean. To assess significance, p-values were tested against an alpha level of 0.05. A multiplicity correction was applied by controlling the 
false discovery rate (FDR) to control for inflated Type 1 error rates. As a result of controlling the FDR, all p-values below 0.025 were significant. 
Furthermore, the effect sizes were either medium (d ⩾ 0.50) or large (d > 0.80). Thus, the results with regard to the primary endpoint lead to the 
conclusion that the formula was adequately validated for all patients. Effect sizes were derived using the formula for calculating Cohen’s d for paired 
sampled t-test.41 (g). ROC curve for observed responders in the total sample (N = 97). The p-value for the Area Under the Curve (AUC) was 
significant (p < 0.001). Accuracy was 0.78. Sensitivity, defined as the ability to identify T + B responders, was 0.78. Specificity, defined as the ability to 
identify T + S responders, was 0.79. Positive predictive value, defined as the proportion of correctly classified T + B responders, was 0.79. Negative 
predictive value, defined as the proportion of correctly classified T + S responders, was 0.78. The combination of the nine inhibition SNPs and the 
seven B-coded SNPs resulted in a greater proportion of correctly classified patients. This combination was therefore superior to the nine inhibition 
SNPs alone. The ROC curve supports the usefulness of the formula at the individual level (Figure 3(g)). The AUC of the ROC curve served as the 
test statistic for the relationship between demarcation formula outcome and response status based on the outcome measure. The hypothesis tested 
was that, in classifying patients as either T + S or T + B responders, the formula would perform above chance level. The AUC was interpreted as the 
probability that, for a given random pair – T + S responder plus a T + B responder – the formula would produce a larger outcome for the former 
than for the latter. ROCs with an AUC in excess above 0.71 indicated a large effect size (d’ > 0.8), and ROCs with an AUC above 0.76 indicated an 
effect size of at least 1. Finally, ROCs with an AUC in excess of 0.80 were generally considered to be ‘good’ and suitable for clinical use.42 The ROC 
curve showed an excellent AUC (Figure 3(g)).
SSE: satisfactory sexual event; d: effect size (Cohen’s d); PRI: placebo run-in; T + S: testosterone 0.5 mg + sildenafil citrate 50 mg; T + B: testosterone 
0.5 mg + buspirone hydrochloride 10 mg; ROC: receiver operator characteristic; AUC: area under the curve.
Figure 3. (Continued)
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indicate that the PPS demarcation formula could also be 
useful in clinical practice, as a companion diagnostic and a 
step towards true personalized medicine.
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